Year: 2019

  • Revance Therapeutics – A Wrinkle-Causing Year

    Revance Therapeutics – A Wrinkle-Causing Year

    Revance Therapeutics - A Wrinkle-Causing YearThe company is a biotech pioneer establishing a new category of long-lasting neuromodulators.
    The Revance Therapeutics stock can be a good addition to the investment portfolio 

    by Guy Avtalyon

    Wednesday was a rough day for shares of Revance Therapeutics (NASDAQ: RVNC). Investors were surprised by lowered the biotech stock for 16.4%  on Wednesday and traded at $16.61.

    Only a few days ago, or the day before, the shares had been rising. But the company submitted an application to the FDA for DAXI in November. On Monday, shares rose over $20 per share until the end of Tuesday’s session. On Wednesday it was announced $17 per share. 

     

    What happened with DAXI?

    For a long time, DAXI is a neurotoxin, but better than Botox, a global favorite. Revance Therapeutics has proof that it works better. Botox sales have risen to $2.7 billion per year and the producer AbbVie has a lot of reasons to be satisfied. 

    But let’s go back to Revance

    FDA’s evaluation of DAXI could take months and we still don’t know if and when it will start. Revance Therapeutics’ partner Mylan announced the possibility to fund late-stage development of DAXI until April 30, 2020. What if FDA doesn’t start its review until then? You see, despite a published good result of DAXI and great expectations for selling it, one paper can disappoint investors. Yes, it is an important paper and a lot of things depend on it. For example, the future of Revance Therapeutics and its partnership with Mylan.

    If Mylan supports DAXI and gives Revance a two-digit percentage on sales, it could deliver a great return. 

    On an investment of $10.000 in less than 2 months, you may have a nice return of $1.047 if you set your stop-loss at 19,25% level from the current price and take-profit at 40,25% level. But once again check yourself.

    Revance Therapeutics had the problematic announcement 

    Revance Therapeutics, Inc. is a biotech company. It develops next-generation neurotoxins for treating aesthetic and therapeutic conditions. On December 4, it announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price of $17.00 per share. 

    Revance has allowed the underwriters a 30-day option to buy up to 975.000 additional shares. The gross incomes from the offering are expected to be approximately $110.5 million. The offering is supposed to close about December 6, 2019. Revance Therapeutics plans to use this net profit of common stock to proceed to fund the commercialization of DAXI. The additional income will spend mostly on research and development.

    Revance Therapeutics

    Revance is fusing new science with the entrepreneurial vision of Silicon Valley. It is a modern biotech company with an innovative approach to aesthetic and therapeutic treatments.

    The company stated on its website:
    “Our lead investigational product, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.”

    It has been completed a Phase 3 program for DAXI in grimace lines. It showed fantastic efficiency and duration, and the company is seeking FDA approval.
    The company is focused on developing products and treatments in dermatology and aesthetics. Its products are RT001, botulinum toxin type A (BoNT-A) for cosmetic and dermatologic treatments. The previous name of the company was Essentia Biosystems, Inc. Under the name Revance Therapeutics, Inc. it is founded in 2002 with headquarters in Mountain View, California.

    As Traders Paradise can conclude the stock price of Revance Therapeutics can easily hit at least $18 in the next 10 days.

    At the moment of writing this article, it is December 05, Thursday, the current price of RVNC stock is $16.840 which is a bit more than yesterday. This stock had a declining tendency for the past 12 months. Biotech stocks are really tricky. But Traders Paradise thinks the stock price could rise significantly in the next 2 months. Over the one year, the price could be almost doubled. Hence, this is a strong BUY stock.

  • Biotech Stocks Are A Good Investment

    Biotech Stocks Are A Good Investment

    Biotech Stocks Are A Good Investment
    The biotech companies have strong earnings growth
    The Nasdaq Biotech Index (NBI) has slightly outpaced the S&P 500 over the past 12 months.

    Biotech stocks are the most impressive, exciting and, at the same time, one of the trickiest assets of the stock market. Biotech firms use technological methods based on science to produce products. The majority of biotech companies are focused on clinical research and the development of new medicines. 

    But the whole industry has a lot of different purposes, the drugs are just a part of that. You can find biotech stocks on genetic experimentation, food modifications, health care, almost everywhere. One thing is common for every single producer: they have to go through a harsh, expensive and intensive experimental process before getting approval for the market.

    The biotech companies have strong earnings growth 

     Discovering the best biotech firms to invest in can be difficult. Laboratory ideas don’t always come to success and frequently biotech stocks are subject to strict regulations and rules.

    What you have to keep in mind is earnings growth. Biotech stocks are giving exactly that. If you are looking for great rewards, the biotech stocks are for you. One thing is important to be noticed here: these stocks carry a big risk too.

    Biotech stocks have great potential

    Well, there is an explanation of why that is. Every company needs time to develop its business, operations, presence in the market. Biotech companies frequently depend on the success of several trials of their products. During that phase, its stock isn’t expensive. Contrary, it can be very cheap. When the company gets approval for a drug or some positive news about testing comes, the stock price can skyrocket. Refusals or bans, though, can cause a disaster. So, for normal investors, it can be difficult to gauge how the testing of some drugs or anything from the field of the biotech industry will end. Well, here is one suggestion. Stay tuned on what the analysts who are well informed in the biotech industry are saying. If you see a stock that is frequently surrounded by bulls, it is a sign that something worth is nearby. 

    Recognize your biotech stock better than anyone

    We will show one example of how to do so.

    Axsome Therapeutics is developing new drugs for the treatment of CNS disorders. Yes, it is clinical-testing stage and biotech stocks can be uncertain for investors. But this stock is remarkably fit for any investor with an aggressive approach to investment.

    AXSM stock has increased over 1.200% in this year. The investors are excited about the upcoming clinical study results. Axsome Therapeutics is in a late-stage study for its AXS-05. It is innovative and important in treating a depressive disorder, so-called MDD. The company is expecting results from another study, a drug for treating treatment-resistant depression, by the end of the first quarter in 2020. Also, the company expects positive results from a study of AXS-05 for Alzheimer’s disease in the first six months of 2020. And stock market analysts are predicting a huge revenue for the company and the shareholders. So, the hint that some biotech stock is a good investment is coming from the news.

    How to pick the best biotech stocks

    Over the past year, the Nasdaq Biotech Index (NBI) has kept up with the market.
    This year has been a hard ride for everyone. But the biotech sector, with its large firms, is definitely catching its pace. The index is rising. We were witnesses of interesting mergers during the past several years that starting to be profitable. Some new technologies are starting to gain excellent results which boosts hope for many patients. The cost of their tests is enormous, it is around $2 billion approximately. Also, it takes almost 10 years until some drug gets permission for distribution and human usage.
    It sounds like a lot of responsibility. Moreover, producers need to form a strong base for future growth.

    If you are focused on biotech stocks you should find biotech companies that are driving cutting-edge therapies. The brands that are well-positioned provide big premiums.

    Traders-Paradise recently wrote about one of them, but stay tuned, there will be more.

  • Fiat Chrysler Stock to Watch in December 2019

    Fiat Chrysler Stock to Watch in December 2019

    Fiat Chrysler Stock to Watch in December 2019
    FCAU could be a solid portfolio addition since Fiat Chrysler Automobiles is a good investment.
    The labor concerns are solved and Fiat Chrysler can switch its attention to its merger with Peugeot owner, PSA Group.

    Of course, you will watch the stocks you like, but our choice of stock to watch in December is Fiat Chrysler. On Monday, December 2, its shares were changed a bit since the Fiat Chrysler stated that the automaker made an agreement with the United Auto Workers (UAW) over the last weekend. It looks that Fiat Chrysler Automobiles will avoid a strike. Previously, General Motors and Ford made agreements with the UAW.

    So, it will be interesting to watch this stock in December and how this agreement will influence the stock price.

    The UAW revealed some parts of the agreement. According to UAW Fiat Chrysler will invest $9 billion to add 7,900 jobs in the next four years. The negotiations were focused on benefits, salary, and job security. The deal is expected to be reviewed by UAW’s national council on Wednesday, December 4. If UAW’s council confirms it, the next step is Fiat Chrysler union members to ratify it. It should be happening on Friday.

    The smart choice made Fiat having in mind how big financial damage experienced General Motors during the UAW strike in September and October.

    General Motors’s revenue declined 1% in the third quarter,  net income fell by nearly 9%. But that is not the end, General Motors easy could experience further downs next year when its Q4 earnings report is expected.

    With this deal, Fiat Chrysler opened a space to continue with the merger with Peugeot owner PSA Group. The past tries to couple with this European car company, didn’t result in a union. 

    The Fiat Chrysler’s problems grow

    The Schall Law Firm announced the filing of a class-action lawsuit against Fiat Chrysler Automobiles N.V. (NYSE: FCAU) for violations of the Securities Exchange Act of 1934 and Rule 10b-5 declared thereunder by the U.S. Securities and Exchange Commission.
    Investors who bought the Fiat securities between February 26, 2016, and November 20, 2019, didn’t have the real data, according to the law firm.

    According to the Complaint, Fiat Chrysler presented incorrect and misleading reports to the market. Fiat joined in a bribery system created to obtain beneficial terms from labor unions for its collective agreements. The top-level management was engaged or had information about the schemes. The law firm said that Fiat’s “public statements were false and materially misleading throughout the class period.” When the market noticed the facts about Fiat, investors experienced losses. Some of them have losses above $100,000.
    The Schall Law Firm represents investors all over the world and specializes in securities class action lawsuits and shareholder rights litigation. 

    Fiat Chrysler (FCAU) stock price

    Fiat Chrysler Stock to Watch in December 2019

    Fiat Chrysler stock was traded at $14.73 on Monday which was a decline of 0,14 %. Today it is $14.760 with an increase of 0.1017%. It is a good company, the stock can provide a good return, so we can say it is a lucrative investment option.

    Based on Traders-Paradise’s calculations, this stock is a good long-term investment. In the 5-years period, the revenue on your investment could be about 40% and the stock might worth above $20 at the end of that period.

    The analysts forecast for Fiat Chrysler Automobiles a median target of $17.85. A high estimate is about $20 and a low estimate is around $12. The future price of the stock is predicted at $28.799 after a year according to some other analysts. On 2019 December 03, the current price of FCAU stock is $14.765 and our data shows that the stock price has been in a downtrend for the past 12 months.

    FCAU stock price has been presenting a declining tendency but Check our tool to determine the best exit strategy.

     

  • Axsome Therapeutics (AXSM) Is A Good Investment

    Axsome Therapeutics (AXSM) Is A Good Investment

    Axsome Therapeutics (AXSM) Is A Good InvestmentAxsome Therapeutics gained 1.70% in the last trading day ( Friday, Nov 29), increasing from $38.71 to $ 39.37. Will the company be able to continue growing?

    By Guy Avtalyon

    Axsome Therapeutics is developing innovative therapies for the treatment of CNS disorders. Yes, clinical-stage biotech stocks can be a risky suggestion for investors. Well, at the same time this stock is extremely suitable for any dynamic investors. If you prefer an aggressive approach to your investment this stock deserves your attention.

    Axsome Therapeutics (AXSM) has jumped over 1.200% in this year. The investors are awaiting the biotech’s upcoming clinical study results excited. Well, the company is in a late-stage study for its AXS-05. It is innovative and important in treating a depressive disorder, so-called MDD to the end of the year. The company is awaiting results from another study, a drug for treating treatment-resistant depression and it will be published to the end of the first quarter in 2020. Also, Axsome Therapeutics expects to present excellent results from a study of AXS-05 for Alzheimer’s disease in the first six months of 2020. 

    To the end of this year, the company is expected to present the results from a late-stage study of AXS-07 in treating migraine and of AXS-12 in treating narcolepsy. Analysts estimate AXS-05 could obtain annual sales of more than $1 billion when approved. 

    The main problem is that Axsome Therapeutics’ results could be failed like it is with so many drugs.
    But if they get a good result this stock will be high rocketed. 

    The current price is $39.37 (Nov 29). This small-cap stock in the S&P 500 had the greatest total return over the past 12 months. It is 959.6%

     

    Why invest in Axsome Therapeutics

    Axsome Therapeutics, Inc can be a profitable investment option for investors wanting good returns. Axsome Therapeutics, Inc quote is $39.370 on December 2. This stock can provide more than 300% of revenue after 5 years since it is expected the price to rise to $160 in the next year.

    Axsome Therapeutics has a median target of $46.50, where a high estimate of $53.00 and a low estimate of $25.00. The median estimate represents a +18.11% jump from the current price. The investment analysts’ suggestion is to buy this stock. 

    Axsome Therapeutics ABOUT

    The company’s market cap is $1.36B. Axsome Therapeutics reported Q3 2019 financial results on Nov 7, 2019.

    Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops innovative treatments for CNS disorders, especially for those with limited treatment possibilities. Axsome’s center CNS product portfolio covers four clinical-stage products, AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is in a phase 3 test in treatment-resistant depression, the same as MDD, and a Phase 2/3 trial in difficulties connected with Alzheimer’s disease. AXS-05 is also being developed for smoking end therapy. AXS-07 is in two Phase 3 trials for the treatment of migraine. AXS-12 is in a Phase 2 trial in narcolepsy.

    AXS-05, AXS-07, AXS-09, and AXS-12 are drug products not approved by the FDA. For more specific information, you have to visit the company’s website. The Company may occasionally disseminate material, nonpublic information on the company website.

    Is AXSM a good investment?

    This company’s liquidity data is interesting: its Quick Ratio is 1.41 and its Current Ratio is 1.41. This shows a good ratio between its short-term liquid assets and its short-term liabilities. So we can easily conclude it is a less risky investment. This stock’s RSI score is at 50.78, which means that the stock is not oversold or overbought.
    The important clinical wins could place this company on the route to produce greater gains. Hence, we think it is a good investment.

     

  • EU Banks Welcome Bitcoin

    EU Banks Welcome Bitcoin

    EU banks welcome Bitcoin on January 10, 2020
    From next year banks in EU banks will offer their customers cryptocurrencies in online banking
    The German lawmaker is the leader in the regulation of cryptocurrencies.

    By G. Gligorijevic

    EU banks welcome Bitcoin??? Yes. In the ever-running war of governments against money laundering and terrorism financing new regulations are being enacted and implemented in many countries on almost regular yearly levels. And the approaching deadline for implementing one such regulation in the EU is good news for all investors and potential investors in cryptocurrencies from this supranational block. The governments of EU member states have until January 10, 2020, time to implement the 5th Anti-Money Laundering Directive (5th AMLD) which brings a sorely needed legal framework for trading and investing in cryptos. Until recently, among the EU legislators existed a strong negative attitude towards the cryptocurrencies. Most often justified by a lack of proper legal framework and the potential for a sinister use of the advantages they are lauded for. But from January next year, such obstacles shall be removed, and crypto trading will be available along with the more conventional banking and investment products.

    What does 5th AMLD bring?

    While most of the public and media is putting the focus on the parts of the new regulations which tighten the AML rules concerning the regulation of real estate agents and precious metals dealers, on the sidelines are left novelties regarding the cryptocurrencies.

    The most important novelty is the implementation of a definition of what is a cryptocurrency. Even though the general public knows what it is and what it is not, this was a crucial moment for making investment and trading with cryptos through traditional institutions possible in the EU. Now the commercial and investment banks will have a precise legal language of what cryptocurrencies are.

    The second crucial part of legal regulations is the definition of a waller provider. This will have the effect of allowing all of the existing financial regulations to be applicable to cryptocurrencies. And such applicability will legally equalize the traditional investment vehicles with the cryptocurrencies.

     

    The impact on traders, investors and common people

    That would be the legal language of it, but what does it mean in simple terms. In the most simple terms, it means that cryptocurrencies such as Bitcoin, Etherum, and others; will be equal to the fiat currencies. Banks will be able to provide all of the traditional banking products to their customers in cryptocurrencies. People and institutions will be able to hold them in their accounts, exchange them for other fiat or cryptocurrencies. But also they will be able to use cryptocurrencies to purchase other financial assets with cryptocurrencies. Bonds, stocks, derivatives, and the likes will be available for purchase. 

    Implementation still lagging

    The deadline for implementation of new AML regulation is fast approaching, but many member states are well behind is this regard. On November 14 this year, Geman’s Bundestag has passed a new bill which now awaits the passage in the upper house of German Parliament, after which ratification by all 16 federal states must follow.

    After this new financial regulation bill becomes the law of the land, Germany will join the likes of Austria, Belgium, Ireland, Greece, Finland, Croatia, Italy, Latvia, and Luxembourg; as another country that has implemented new rules and made cryptocurrency investing and trading possible. But, Germany is an economic powerhouse and one of the financial centers of the EU, thus this move has a higher significance than meets the eye. Germany is not just another country. It is a country with a GDP amounting to 22% of the whole block, and its financial regulations and market trends are closely watched and often copied by other member states.

    The public reaction on how EU banks welcome Bitcoin

    The public reaction to the new bill was somewhat as expected, some have welcomed it while others decided to criticize less novel potential impacts. 

    The Association of German Banks has reacted positively to the news that EU banks welcome Bitcoin. This comes as no surprise bearing in mind how much this institution was expressing support for regulating cryptocurrencies, and thus bringing it into a legitimate system of banking in Germany out from the grey zone it existed till now. The criticism can be boiled down to repeated yelling “banks are crooked”. And these concerns do have merit. In the past, commercial and investment banks did, and often still do, behave in a predatory way. But that is not the reason to fight against bringing the cryptos into the world of traditional banking. It is a reason to better regulate traditional banks, and protect their customers. After all, decreasing the power of banks over common people was one of the philosophical reasons for the invention of cryptocurrencies.

    In the end, a long time considered as an obsession of pimpled geeky libertarians cryptocurrencies is about to enter the game after January 10, when the second-largest economy per GDP makes them part of its regulated financial system.

     

     

  • Cannabis Stocks Are Not All Equal For FDA

    Cannabis Stocks Are Not All Equal For FDA

    Cannabis Stocks Are Not All Equal For FDA
    FDA sent numerous warnings about the CBD, substance found in cannabis.
    The stock prices of important cannabis stocks are dropping on a new warning from the FDA.

    By Guy Avtalyon

    Cannabis stocks are under attack. On Tuesday the US Food and Drug Administration (FDA) published new guidance on CBD. FDA notified that CBD can cause liver damage and also, some other injuries might be caused by using CBD.

    This information caused blast to the medical cannabis producers especially among those publicly listed on markets. Those companies have plans, they are investing in development, researching, and have licenses. We are talking about Canadian producers and their investors that were looking for the area for selling cannabis products and the US seemed to be that one. And now FDA issued a statement that their products are not safe for humans. Okay, even if it is true, how FDA can explain that GW Pharmaceutical’s CBD products are safe. This isn’t an attack on GW Pharmaceutical, it’s contrary, why other companies are forbidden to make health claims for its products use. 

    The FDA announced late Monday it is pointing on 15 private companies that are illegally selling products with CBD.
    The regulator said, “there is very limited available information about CBD, including about its effects on the body.”

    What is CBD?

    CBD is a non-intoxicating cannabis compound but it lives in regulations’ vacuum. FDA has approved GW Pharmaceutical’s GWPH drug that contains CBD, a drug for the treatment of childhood epilepsy but, FDA told the other producers that they have no permission to include this ingredient to food or drinks. The reasons are already mentioned.

    “Not so fast,” wrote MKM analyst Bill Kirk. “The FDA’s statement includes some balloon-bursting language,” MarketWatch reported.

    Cannabis stocks were crashed again on Tuesday. That was the signal for analysts to make new estimations and to update the previous.

    Cannabis legalization is slow both in Canada and the US. That causes the black market to grow, while the legal companies are struggling to increase revenue and become profitable. Some of them had to cut selling, cancel the agreements, and save the cash for the following days in expectation for the issue to be solved. 

    But investors have different sentiment and the stock prices of these companies are dropping.

    FDA influences the price of cannabis stocks

    The FDA’s update is in line with a note from the regulator’s former commissioner, Scott Gottlieb. He tweeted: “FDA’s actions on CBD show any available pathway – FDA issuing a regulation, new dietary ingredient notification for supplements, or a food additive petition for human or pet food – will require extensive studies and industry data to address serious safety concerns identified by FDA.”

    Extensive studies? Okay. Is there anything that they are working on? If yes, tell them to hurry up, the health benefit is in question. Tell them to have in mind a relief of pain and mental suffering. How about that?
    And, what they were doing for all the time? Haven’t yet find anything about cannabis? So many studies are already done. 

    The most important cannabis stocks trade in CBD products. Some of them were failing in trading after the FDA’s announcement. Canopy Growth fell by a bit more than 1%, and Tilray was falling by 3%. But they are connected to the section. The worse came for Charlotte’s Web which stock was down by almost 8% and we are speaking about the leader in the CBD market. 

    One stock was especially successful on that day. GW Pharmaceuticals was up. 

    Cannabis Stocks Are Not All Equal For FDA
    (The image was taken on Nov 27.)

    Guess, it has FDA approval for selling the CBD products. GW Pharmaceuticals is a unique one. Yes, their stock price was only slightly up, if the rise of 1.62% is slight. But still.
    The FDA said the next step is to make a framework to allow companies that are producing CBD-based goods to deliver them to the market. Oh, yes, they have to wait for clinical trials. Only after that, the market will be opened to them.
    Until then, investors will sell in panic cannabis stocks or hold them till the better times.

     

  • Target Corporation The Hot Stock In The Market

    Target Corporation The Hot Stock In The Market

    Target Corporation The Hot Stock In The Market
    Target Corporation’s market capitalization is $64.11B with the total outstanding Shares of 179.
    The company has an EPS growth of 8.06% for the coming year.

    By Guy Avtalyon

    Target Corporation (NYSE: TGT) has made excellent moves in the late years. They developed a lot of benefits to customers. Besides remodeling their stores, they added same-day fulfillments, in-store orders for goods, and delivery through Shipt and Drive Up. The result was that the TGT stock price rose almost twice in 2019.

    The best of all, the holidays are coming and it looks that Target is prepared for an extra rise in sales. Target Corporation has added 50 million paid hours and has increased the number of employees, all of this with the expectation that the sales will grow over the holidays. To make a better offer to customers, the company added 10.000 new toys, including Disney’s products and numerous cheap gifts that you have to pay less than $15. Moreover, they made a deal with Toys R Us to improve online sales. 

    So, Target looks prepared for Black Friday and holiday shopping season.

    TGT price was $126.89 yesterday (Nov 26) and marked an increase of 1.36% or $1.70.

    Investors were fascinated with Target Corporation

    Target has almost doubled its market value this year. Its quarterly reports fascinated investors. Over a third-quarter, Target rose its comparable sales by 4.5%. That drives the stock price to the sky.

    The company’s digital comparable sales increased by 31% in Q3. The great contribution came from Its same-day fulfillment services. That should provide a Target to have strong traffic in the fourth quarter.

    It is possible for Target’s earnings to go up to 10%.  

    If you want to trade TGT stock Traders Paradise tool shows that you can set up stop-loss at  -2% and take-profit level at +1.75%, which will give you a nice return of $74,78 in less than two days on your investment of $10.000. But it is better if you check it on your by your own.

     

    The future of  TGT stock

    We at Traders-Paradise think Target Corporation stock is a good long-term investment.
    If you are looking for stocks with good returns, Target Corporation can be a profitable investment option. TGT is quoted at $126.89 today (2019-11-27).
    Based on historical data, but more on our analysis,  investors may expect an increase in TGT stock price after five years it can easily reach  $207 with revenue of more than 60%. If you invest $10.000 in this stock today after five years your investment could be over $16.000. The analysts’ recommendation is a strong BUY for this stock. This year Target is sixth-best performing stock in the S&P 500 index.

    About Target Corporation

    “Expect more. Pay, less.” This is the company’s motto from the early days. Target Corporation is founded by George D. Dayton, a New York businessman who’s first interest was the banking and real estate. He started this business on Nicollet Avenue, Minneapolis by opening the Dayton Dry Goods Company, today is known as Target Corporation. Dayton was head of the company until he died in 1938. Later, his son and grandsons developed the company into a national retailer.

    The first Target store started on May 1, 1962. It was a branch of the  Dayton’s department store offering “a new kind of mass-market discount store that caters to value-oriented shoppers seeking a higher-quality experience.”

    Its main rival is Walmart with prices hard to beat, and instead of that Target appeared as “cheap chic” by recruiting well-known designers like Michael Graves, Tracy Reese, or Lilly Pulitzer. This great tactic has made Target retail with richer customers than Walmart’s. Honestly, even the wealthiest Americans like to purchase at Target. Even the people with a net worth above $5 million are shopping there.

     

  • Walmart Eagerly Awaits Black Friday and Cyber Monday

    Walmart Eagerly Awaits Black Friday and Cyber Monday

    Walmart Expects Black Friday and Cyber Monday To Come
    Walmart is one of the biggest companies in the world and capable to resist the competition.
    The stock price dropped but it easily can go up very soon

    Walmart (NYSE:WMT) is transforming and this retailer is ready for Black Friday and Cyber Monday. Everything is in place, so shopping can start. These two holidays are a great test for Christmas. After Black Friday and Cyber Monday, the possibility for Walmart’s stock price to rise is real and even before Christmas. The current price is $118.92 and it dropped by 0.37% from the previous price. But the price rose after hours to &118.95.

    Walmart Expects Black Friday and Cyber Monday To Come

    What makes us think shopping will increase?

    First of all, the unemployment rate is lower than in the last 50 years, job growth is stable, salaries are rising. The St. Louis Fed published that the personal savings rate is at 8.3% which is the highest level since 2012. So, Americans will spend their money on holidays, there is no doubt. 

    The holidays are great for retailers and Walmart plays a big role since it has been transforming and has been aggressively investing in online. Three years ago Walmart bought Jet.com, a US online retailer and took a large stake in the JD.com, online retailer in China.

    Walmart grew its annual profit forecast because quarterly earnings beat estimates. Its shares have risen 26% and trade at 24 times earnings. 

    Well, when it comes to food, Walmart is ready. The grocery is very important for the company’s online business. Walmart customers can purchase groceries online, with unlimited delivery for $98 a year or $12.95 a month.
    E-commerce is a field where  Walmart can get this holiday season since online shopping is supposed to grow by 14% to 18% gaining $149 billion.

    But Walmart has already made profits. Walmart reported third-quarter e-commerce sales rose 41%, driven by growth in online grocery shopping. But Thanksgiving falls on Nov. 28 and the holiday shopping season is shorter by six days. This gives the company less opportunity for sales. 

     

    As always there is Amazon, Walmart’s rival. To beat the competition, Amazon announced some beneficial for its Prime members. Not for all, but still the grocery delivery will be free of charge.
    Management at Walmart announced the lower prices from electronics to playthings. Walmart, also, has shown that it can balance the other features of its businesses despite the Trade war.

    Walmart started offering holiday sales almost a week before Halloween this year. Well, the company called it Early Drop Deals, not Black Friday sales. The company opened its doors for the customers and made their Black Friday purchasing available earlier. Making this, the company actually spread Black Friday’s shopping over more days. 

     

    Walmart stock price and its future

    Walmart’s stock price dropped by 0.37% on  Monday, November 25. Now it has 3 days of dropping in a row. This could be an early signal the risk will be raised somewhat for the next few days and the stock price may slightly drop further. 

    Walmart is currently in the lower frame of a small and weak rising trend in the short term. This is usually a signal for a good buying opportunity. This short-term trend shows the stock is likely to rise by around 5% in the next 3 months and stay between $124 and $128.

    But Walmart stock is a good long-term investment since, as Traders Paradise can see, this stock is going to be profitable over a long period offering the revenue of almost 65%. Speaking about 5-years investment, for example, if you invest $1.000 right now your investment may grow to $1.600 at the end of that period. 

     

    Company’s ABOUT

    Walmart is one of the most profitable retailers in history. It is one of the most successful and well-known companies in the world.
    The company was founded in 1962 by Sam Walton, in Rogers, Arkansas with one store. To the end of 1968, the Walmart chain was expanded outside Arkansas and later opened the stores in every US state. In 1995, Walmart opened its first stores in Canada.
    From 1990, Walmart is the largest retailer in the U.S. and began to expand abroad, opening a store in Mexico and opened stores in the U.K., Germany, China.
    By 1999, Walmart wasn’t only the biggest private employer in the U.S. but in the whole world. Today it is the 29th company in the world, as Amazon, Alphabet, Microsoft or Apple with a host of Chinese companies, have passed Walmart by.
    By the second decade of this century, the chain had increased to over 11,000 stores in 28 countries.

     

  • The Kraft Heinz Company Is Bottoming

    The Kraft Heinz Company Is Bottoming

    The Kraft Heinz Company Is Bottoming
    The packaged-food giant reached rock bottom and positive signs are unfortunately weak. They are not enough to warrant a buy right now.

    The Kraft Heinz Company (NASDAQ: KHC) reported third-quarter 2019 financial results on October 31. The company reported lower net sales and higher input costs. So, the third quarter performances for this company were a lot below their potential but still, the company showed growth in comparison to the first six months this year.

    Kraft Heinz CEO Miguel Patricio said: “We are making good progress in identifying and addressing the root causes of past performance, as well as setting our strategic direction. Although there is still much work ahead, we’re encouraged by our improving performance, and are even more confident in our ability to turn around the Company and set a path of long term growth and profitability.”

    The Kraft Heinz Company results

    Net sales were $6.1 billion, and it was 4.8% below than it was in the same period last year.
    Net income increased to $899 million and diluted EPS increased to $0.74. Adjusted EBITDA declined 7.8% to $1.5 billion. The drop was caused by the drop in the United States and Canada, but there are higher overall corporate expenses also.
    The Board of Directors of the Kraft Heinz Company announced a quarterly dividend of $0.40 per share of common stock. It will be payable on December 13, 2019.
    The KHC stock was traded at $30.54 on Friday, November 22, which is an increase of 0.99%.

    The Kraft Heinz Company Is Bottoming

    Should you buy the Kraft Heinz Company stock?

    The analysts offering 12-month price predictions for Kraft Heinz Co have a median target of $32.00. Their high valuation is at $38.00 and a low at $23.00. The median shows a 4.78% rise from the current price.

    The recommendation is to hold stock in Kraft Heinz Co. 

    But the other group of analysts is pretty much sure that the Kraft Heinz stock couldn’t have good returns. That’s the reason why they claim that this stock is a bad and high-risk long-term investment. Today’s quote (Nov 25) for Kraft Heinz is $30.53 which is lower than on Friday. 

     

    Traders-Paradise opinion

    Having the current price of KHC stock in our mind and with the knowledge that the stock price had a downtrend for the past 1 year, we in Traders-Paradise are not sure is this stock is good as a long-term investment. We are close to thinking that this stock could easily drop significantly in the future hitting a decline of over 100% and to end up worthless. So, we suggest staying away from this stock if you are seeking a new addition to your investment portfolio. This is important especially if you are a new player on the market and don’t have enough experience. 

    This stock is trading in bear markets, which is harder for new traders.

    But if your plan is to buy and hold Kraft Heinz stock for a short time, for example, the next 10 days or two weeks, it can be a good choice. As we can see, the stock price could hit around $35 in the next several days.

     

    Bottom line

    The price line shows the possibility of zigzag running to the end of this year. After the end of this year, we are afraid that this stock will gain further declines.

    Our opinion comes from the suspicion that the company is not able to answer the challenges of predicting consumer demands. In its latest report, we couldn’t find that the company is ready to offer new products or to react to rivals’ improvements.
    The Kraft Heinz Company survives 150 years of challenging and produced some of the products well-known over the world. Yes, it is one of the largest global food companies, but the new era is already here and the company has to catch the moment.
    The point is that General Mills or Nestle are better choices in our opinion.
    We can recognize some possible upward movements, but they are weak and don’t provide enough reasons to buy this stock now.

     

  • The Top Winners And Top Losers In The Market

    The Top Winners And Top Losers In The Market

    The Top Winners And Top Losers In The Market
    Good and bad news may have a great influence on the stock price
    These two stocks show both sides, winning and losing on the market

    Top winners and top losers last week in the stock market is easy to find but what lies behind sometimes looks like a tricky part.
    For example, EyeGate Pharmaceuticals, Inc. (EYEG) is one of the winners last week. But what did make it become a winner? 

    The news about the high quality of its ocular bandage gel eye drops is able to provoke investors’ sentiment and confidence in the company. What did that news show us? The company is investing in research and development and improve its products. 

    And shares rose by more than 90%.

    The news that the company’s innovative eye-drop bandage worked better than the usual kinds of care. Its bandage contact lens, for the patients in need of corneal wound repair, is better than the others. EyeGate intends to submit a new application to the Food and Drug Administration in the first half of 2020.
    EyeGate CEO Stephen From said: “If approved, it will be the first product indicated to repair corneal defects, as well as the first prescription hyaluronic acid eye drops in the U.S.,” stated in a release. The company is expecting additional data this week. 

    And what happened? 

    The stock price jumped on good news.EyeGate shares rose on data for eye treatment data.

    The Top Winners And Top Losers In The Market

    Top winners and top losers last week are always the subject of investors’ attention. Yes, the stock price may jump on bad news too as well to drop on a good. Traders-Paradise wrote about it already.

     

    Let’s go a bit deeper in top losers. One of them is Pure Storage, Inc. (PSTG).

    Pure Storage (PSTG) stock dropped Friday after the company reported Q3 results on Thursday. The results missed Wall Street estimates. Pure Storage is a provider of data system technology. On Thursday last week, they reported an adjusted profit of 13 cents/share but Wall Street expected a profit of 9 cents. That was good but revenue of $428.4 million missed the estimation of $440 million. The company’s revenue was $11.4 million below estimation.

    The stock price dropped despite the fact that the company’s revenue grew 15% in comparison to the same period last year. The problem arose due to the fact that it was the slowest growth over 4 years.

    Pure Storage stock dropped 15.1%, closing at $16.86 on Friday.

    Top gainers often continue to rise and reach new highs with strong fundamentals. When a stock continues reaching new highs it’s essential to pay attention since there might be a retracement.

    Bottom line

    What Traders-Paradise thinks about those two stocks, the top winners and top losers?

    News reports about EYEG stock have been trending positive lately. That may easily cause optimism among investors and hence, the good news is likely to affect the stock price rising in the near future. So, this stock has a BUY signal. 

    EyeGate Pharmaceuticals, Inc stock is a good long-term investment. If you are seeking stocks with stable returns, this one can be a beneficial investment choice. EyeGate Pharmaceuticals, Inc was traded at $7.090 last Friday. We are expecting a further increase in the next years. This stock may reach $14 in the next 4 years. If you invest $1.000 today you may have $2.000 at the end of that period since the revenue is expected to be about 100%.
    This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 26.89 million shares bought and sold for approximately $453.37 million.

    On the other hand, Pure Storage, Inc stock can be a bad long-term investment and high-risk investment option.
    Pure Storage, Inc was traded at $16.860 on Friday last week. It dropped from $19.85 and that marked a fall of 3 days in a row. Volume has grown in the last day by 21.42 million shares but on dropping prices. The Traders-Paradise opinion is the stock will continue to fall in the days ahead and your investment may be decreased in the future.